Category Archives: Stem Cell Doctors

Slidell mom with months to live, couldn’t afford to fight ‘very treatable’ cancer – WWLTV.com

They told me if I was going to have cancer, this is the one to have because it's very treatable. That gave me a lot of hope then, it wasn't going to be this bad.

SLIDELL, La. A Slidell mother in her late 40's, was hoping for a chance to try an experimental treatment to save her life, but she kept facing obstacles that now may have taken away her chances for survival.

It's a battle that many others in her situation face. They don't have access to the latest medical treatments.

Now the system continues to fail a cancer patient who is running out of time.

It's a moment in time most people might take for granted.Aparent sitting at the dining table helping a child with homework.But not for a single mom of three, NicoleHarris.

That is the hardest part. It's very hard. It breaks my heart. I feel like I'm failing them, Nicolle Harris, 49, said crying about her illness taking her away from her children.

It all started with back pain two years ago.Nicole was told it was arthritis.Several months went by.She started going down.

At that time I couldn't walk. I couldn't bathe myself. I couldn't do anything.

Then from blood work and a bone marrow biopsy,the long-awaited diagnosis.

I was terrified because it's cancer, said Harris.

Multiple Myeloma is a cancer of white blood cells called plasma cells. That's what fights infections by making antibodies.

They told me if I was going to have cancer, this is the one to have because it's very treatable. That gave me a lot of hope then, it wasn't going to be this bad, she remembers.

There was radiation, chemo, and a stem cell transplant. That failed immediately. Then more chemo, and more chemo, eight treatments in all. Then new hope, a clinical trial at MD Anderson in Houston. But soon those hopes vanished.

There's no way I could come up with that kind of money. I mean I'm sitting here with a treatment that could give me years right in my grasp, and I couldn't have it, Harris said through tears.

You see, Nicole is on Medicaid. Being this sick, she could no longer work cleaning houses with her friend. The initial assessment in Houston was nearly $40,000. Medicaid would not pay because it was out of state.

Through a chain of E-mails forwarded several times over, Medical Watch learned of Nicole's desperation. We reached out to the LSU Health Cancer Clinical Trials program.

The state of Louisiana has poorer outcomes than the rest of the country with respect to a variety of cancers, and much of this is due to access of care, explained Dr. John Stewart, Director of the LSU, LCMC Cancer Center.

Dr. Stewart has just come back to Louisiana for this position. His goal is to create a system that gets rid of health disparities in cancer care.

I think that it is unacceptable that a patient has to leave the state to get care for complex malignancies, and so one of the drivers for our cancer center is to offer state-of-the-art multidisciplinary care for cancer at home, said Dr. Stewart.

The Louisiana Cancer Research Center is already home to many national cancer clinical trials with the latest investigational treatments. Dr. Stewart wants to grow that program. And that's where hope was reborn for Nicole. LSU Health doctors lined her up with that same clinical trial in Houston, opening here in New Orleans.

That means the world to me. It gives me hope, like I have a chance to be with my kids for a little bit longer. Instead of three months, I could have three years, she said.

But just days ago, again shattered hopes. In the months-long delay, Nicole's plasma cell numbers have plummeted. Even though the clinical trial is now in her own backyard, she no longer qualifies for that new, investigational treatment. She is running out of time, and is already out of money.

I've been trying for a year and a half just to get disability. I haven't even been able to get that yet. I was approved medically, but not financially because all the stimulus payments were in my account, and so I had to start all over again and they said it could be five months or more, Harris lamented.

But if the doctors are right, she doesn't have five months. Multiple bones are breaking. There's excruciating pain. Nicole's mother has moved in to her Slidell home to care for her.

When asked what's getting her through this ordeal, she replied crying, My kids. Yeah, I don't want to leave them.

Her daughter says she gets sad sometimes and copes with alone time.

I will just I guess sit in my room and I guess hug a pillow, said fifth-grader, Alaina Harris.

It's driving her oldest, a senior in high school,and really the man of the house,to focus on grades and get into LSU,then to veterinary school.

When asked where does his resilience comes from, Damien Harris replied with a chuckle, My mom, and my Maw Maw. They're both hard workers.

And while she can watch her three children with tremendous pride,Nicole now waits for the last chance at hope.Doctors want to change her chemo medicine. It has a 10 percent chance of helping.

But for nearly two weeks, doctors have been waiting for Medicaid insurance approval. Two weeks: that's an eternity in Nicole's life.

Nicole now has lymphedema in her hip and leg. That is a build-up of fluid when the lymph system is blocked. The earliest a doctor from her original physicians office can see her, is two weeks from now.

Read the original post:
Slidell mom with months to live, couldn't afford to fight 'very treatable' cancer - WWLTV.com

What Are New Medical Solutions That Can Help Treat Patients? – iLounge

The biomedical field is constantly working to make new medical solutions that can help treat patients with various illnesses and conditions. Today, there are numerous medical solutions used today to help ease medical treatment for patients. These solutions include new medical devices, implants, software used to run medical equipment, and information technology systems.

The following are some of the most popular medical technologies that are used today:

Information technologies are another type of technology used today in medicine. For example, imaging systems let doctors examine patients like never before by allowing them to see inside a persons body without performing surgery first. One famous example of this type of medical solution is 3-D imaging software that uses pictures taken with an X-ray machine to give doctors a model to track health changes over time. Another example includes using information technology systems to control medical equipment or devices through smartphone computer programming or apps.

This type of technology allows doctors to use medical equipment with greater accuracy and helps make their work easier. For example, different types of imaging software help provide more transparent images for radiologists when they read X-rays and MRIs. This helps with making a diagnosis quicker. Thats why most hospitals would prefer to work with Wound Care, a web-based EHR tool. Such tools help record patient vitals and wound assessments to track each patients progress and provide better treatment.

These products can be used as medical solutions for people who want to check their health but dont want to visit a doctors office. Wearable health technologies include everything from smartwatches that measure heart rate and blood pressure functions to fitness trackers that help wearers monitor daily activity levels. Even Google has made its smart contact lenses that can track glucose levels for people with diabetes. However, these devices are designed specifically for individuals suffering from chronic diseases such as arthritis or Parkinsons disease in many cases.

Synthetic biology and genetic engineering tools are a technology used to treat illnesses or conditions that affect organs in the body. For example, if a patient has heart disease, they may need a new heart valve. In this case, doctors can use synthetic biology and genetic engineering tools to create a different kind of heart valve from those typically made from cow tissue. These valves have been tested on animals, and now researchers are testing them on humans as well.

Laboratory-grown organs are another medical solution used to help treat patients who need transplants for certain diseases or conditions that may have caused organ failure. A typical example is how stem cells taken from bone marrow can be turned into blood cells and then used to help treat patients with leukemia. Other types of laboratory-grown organs being tested in clinical trials today include partially functional livers and lungs grown from stem cells.

Medical equipment is another technology doctors can use when treating patients. For example, medical imaging devices like CT scanners and MRI machines help provide images of the bodys internal structures for diagnosis so doctors can see problems most other methods cannot detect. Another type of medical equipment includes surgical robots that can be moved by a computer program to perform surgery on a patient. This reduces the need for an incision since some procedures only require small openings or ones that heal very well without stitches or staples closing them up afterward.

Stem cells and stem cell therapies are a type of medical solution used to treat patients who have conditions that can be life-threatening or cause other severe complications. For example, patients with leukemia may need transplanted blood cells from healthy donors. In this case, doctors can use stem cells to develop those types of blood cells that will provide the best chance of curing the patients cancer without harming their body.

Other examples include using cord blood stem cells from newborns to make different kinds of healthy blood and immune system cells for older children and adults with certain diseases or using skin or other non-embryonic stem cells to make insulin-producing pancreatic beta cells for people diagnosed with diabetes Type 1.

Overall, biomedical technologies have been beneficial in making it easier for doctors to diagnose and treat their patients. Thanks to these technologies, many patients can live long, healthy lives with their illnesses or conditions under control. As technology continues advancing over time, even more, advanced solutions will come out, which should further help improve patient care. However, the use of new medical solutions must be approved by a doctor before being used on a patient.

Continue reading here:
What Are New Medical Solutions That Can Help Treat Patients? - iLounge

Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights – PRNewswire

SEATTLE, Nov. 18, 2021 /PRNewswire/ -- According to Latest Report, The global cell and gene therapy marketis estimated to account for 47,095.2 Mn in terms of value by the end of 2028.

Genetic mutations can lead to a wide range of serious malfunctions at the cellular level, including diseases such as cancer. These treatments use "living drugs" to repair damaged tissues and replace diseased organs, and they have the potential to cure a wide variety of ailments. In addition to regenerating damaged organs, cell and gene therapy can cure cancer, and the treatment process is fast-paced, with significant progress made in recent years. For the cell and gene therapy industry to reach its full potential, early interaction with payers and regulators is crucial. This will facilitate a fast-tracked clinical trial. While embracing new platform technologies is challenging, early collaboration with other industries will ensure a faster path to market for the new therapies. In addition to this, a play-to-win attitude is critical to success in this field. The success of gene and cell therapies will depend on achieving clinical and research goals.

Request for Sample Copy @https://www.coherentmarketinsights.com/insight/request-sample/2475

Market Drivers

1. Increasing incidence of cancer and other target diseases is expected to drive growth of the global cell and gene therapy market during the forecast period

With growing incidence of cancer and target diseases such as measles and tuberculosis, the adoption of gene and cell therapy has increased. According to the World Health Organization (WHO), in 2019, around 1.4 million people died from tuberculosis worldwide with around 10 million people being diagnosed with the same. According to the same source, in 2018, around 9.6 million died due to cancer with over 300,000 new cases of cancer being diagnosed each year among children aged 0-19 years across the globe. Gene therapy uses genes to treat or prevent disease, where it allows doctors to insert a gene into a patient's cells instead of using drugs or surgery. Therefore, it has the potential to completely treat genetic disorders.

2. Growing investments in pharmaceutical R&D activities are expected to propel the global cell andgene therapy market growth over the forecast period

Key pharmaceutical companies in the market are focused on research and development activities pertaining to gene therapy. Currently, gene therapy is being widely researched for various diseases including cancer, cystic fibrosis, hemophilia, AIDS, and diabetes. For instance, in November 2021, Sio Gene Therapies reported positive interim data for gene therapy trial of Phase I/II of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis, a genetic disorder that progressively destroys nerve cells in the brain and spinal cord.

Market Opportunity

1. Increasing demand for cell and gene therapies can present lucrative growth opportunities

The demand for cell and gene therapies is increasing with growing cases of genetic disorders, chronic diseases, etc. According to the Cystic Fibrosis Foundation (CFF), in the U.S., over 1,000 new cases of cystic fibrosis are diagnosed each year. Moreover, According to the WHO, the number of people with diabetes has increased from 108 million in 1980 to 422 million in 2014. According to the same source, in 2016, around 1.6 million deaths were directly caused due to diabetes. Cell and gene therapies have the potential to treat the aforementioned diseases.

2. Growing regulatory approval can provide major business opportunities

Key companies are focused on research and development activities, in order to gain regulatory approval and enhance market presence. For instance, in March 2021, Celgene Corporation, a subsidiary of Bristol Myers Squibb, received the U.S. Food and Drug Administration (FDA) approval for the first cell-based gene therapy Abecma indicated for the treatment of multiple myeloma.

Buy This Premium Research Now @https://www.coherentmarketinsights.com/insight/buy-now/2475

Market Trends

1. Stem cell therapy

In the recent past, stem cell therapies have gained significant importance across the healthcare sector. Stem cell therapy has the potential to treat tissue damage and have low immunogenicity. Furthermore, it can enhance the growth of new healthy skin tissues, improve collagen production, stimulate hair development after loss, and can be used in the treatment of various diseases including Parkinson's disease, Alzheimer's disease, cancer, spinal cord injury, etc.

2. North America Trends

Among regions, North America is expected to witness significant growth in the global cell and gene therapy market during the forecast period. This is owing to ongoing clinical trials combined with key companies focusing on R&D activities pertaining to cell and gene therapy. Moreover, the presence of key market players such as Thermo Fisher Scientific, Takara Bio Inc., Catalent Inc., and more are expected to boost the regional market growth in the near future.

Competitive Section

Major companies operating in the global cell and gene therapy market are Thermo Fisher Scientific, Merck KGaA, Lonza, Takara Bio Inc., Catalent Inc., F. Hoffmann-La Roche Ltd, Samsung Biologics, Wuxi Advanced Therapies, Boehringer Ingelheim, Novartis AG, and Miltenyi Biotec.

For instance, in July 2021, Minova Therapeutics Inc. entered into a collaboration and license agreement with Astellas Pharma Inc. for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.

Global cell and gene therapy Market, By Region:

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2475

About Us:

Coherent Market Insightsis a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contact Us:Mr. Shah Senior Client Partner Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: [emailprotected] Website: https://www.coherentmarketinsights.com Follow Us:LinkedIn |Twitter

SOURCE Coherent Market Insights

See the original post here:
Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights - PRNewswire

FMQs: Senior Glasgow doctor warns claims doctors act in secret or conceal information could damage public confidence as Andrew Slorance widow claims…

Dr Scott Davidson, deputy medical director at NHS Greater Glasgow and Clyde, refuted claims made in Holyrood on Thursday around the death of Andrew Slorance and warned the allegations could damage the publics confidence in medical care.

The comments came after First Minister Nicola Sturgeon said the Scottish Government would not tolerate cover-ups or secrecy, after Louise Slorance said she had only found out her husband, who was being treated for cancer at Queen Elizabeth University Hospital (QEUH), had picked up a deadly fungal infection after trawling through his medical records.

A separate statement from NHS Greater Glasgow and Clyde said the health board did not recognise the claims being made in relation to Mr Slorances death.

Dr Davidson said: My heart goes out to Mr Slorances wife and loved ones as they continue to mourn his loss. We are reaching out to the family and very much hope they will take up our offer to discuss their concerns.

On some of the wider claims being made, there should be no doubt that as clinicians, our primary aim is to provide professional care and treatment for our patients and support their loved ones.

"We dont act in bad faith or attempt to conceal information and that applies equally across the organisation to all of our staff, both clinical and non-clinical, and to suggest otherwise is not acceptable and has caused considerable upset to all of our hard-working and committed staff.

He added: It is also of concern to us, as clinicians, that this could damage the publics confidence in the quality of care we provide. I hope that by meeting with the family, we can explain in detail the care provided to Mr Slorance, answer any questions they may have and provide some comfort going forward.

Speaking earlier at First Ministers Questions, Ms Sturgeon described Mr Slorance as someone she knew very well and a greatly valued member of the Scottish Government team.

She said the chief operating officer of NHS Scotland had raised the claims with NHS Great Glasgow and Clyde.

Mr Slorance, who was head of the Scottish Governments response and communication unit, went into hospital to be treated for cancer in October last year.

Scottish Labour leader Anas Sarwar described the failings at the hospital as the worst scandal of the devolution era.

Ms Sturgeon said: First of all, I can assure the chamber that I have read Louise's words very closely.

"Firstly, because I will always do that, when relatives of those who have died or received substandard care in our National Health Service, because that's part of my duty. But in this case obviously I have done that because Andrew was someone I knew very well.

"He is deeply missed by everyone who had the privilege of working with him and that certainly includes me.

"I think I first met Andrew on the very first day I served in government back in 2007. He made an exceptional contribution to the Scottish Government and my thoughts are often with his loved ones, in particular his wife and his children.

Read More

"My officials have engaged already this morning with Greater Glasgow and Clyde health board, so that the concerns that have been raised are properly investigated.

"We will do everything possible to ensure his family get the answers that they are seeking and also consider very carefully whether the concerns that have been raised by Louise Slorance have raised wider issues that require to be addressed.

Ms Sturgeon added: The chief operating officer of NHS Scotland has contacted Greater Glasgow and Clyde this morning to start to establish the facts and I've asked for information to be available later today and then we will assess what further steps required to be taken.

"I will not this government will not tolerate cover-ups or secrecy on the part of any health board. Where there are concerns about that we will address those concerns.

During his time in hospital, Mr Slorance tested positive for Covid-19 and another life-threatening infection, both of which his widow believes he contracted while at QEUH.

The 49-year-old had been fighting a rare and incurable cancer mantle cell lymphoma for the previous five years.

Mrs Slorance only discovered the fact her husband had been infected with the common fungus, aspergillus, which can be dangerous if it infects those with a weaker immune system, when she requested a copy of his medical records.

A public inquiry is underway to investigate the construction of the QEUH campus in Glasgow and the Royal Hospital for Children and Young People and Department of Clinical Neurosciences in Edinburgh.

The inquiry was ordered after patients at the Glasgow hospital died from infections linked to pigeon droppings and the water supply, and the opening of the Edinburgh site was delayed due to concerns over the ventilation system.

Mr Sarwar said there was a culture of cover-up, denial, and families being failed in the Queen Elizabeth hospital.

He said: From start to finish, the Queen Elizabeth University Hospital scandal has happened under Nicola Sturgeons watch. She was health secretary when the hospital was commissioned and built.

And she was First Minister when it was opened. So she must answer why, despite everything that has happened, do we still have a culture of cover-up, secrecy and denial with families being forced to take on the system to get the truth?

The Glasgow health board leadership has lost the confidence of clinicians, patients, parents and the public. Given everything that has already happened, and everything that has already been uncovered, why is the leadership still in place?

Mr Sarwar added: Not a single person has been held accountable for the catastrophic errors at this hospital. In any other country in the world, there would be resignations and sackings. But under this government its denial and cover-up.

How many more families have to lose loved ones before anyone is held to account?

A statement from NHS Greater Glasgow and Clyde said: Our thoughts and deepest sympathies remain with the family of Mr Slorance.

"At all times we have been open and honest with the family about the treatment provided and we are reaching out to them to further discuss the issues they have raised. After an initial clinical review, we are confident that the care and treatment provided was appropriate and we do not recognise the claims being made.

Infection control procedures at the QEUH are rigorous and of the highest standard. The hospitals public inquiry is currently underway and we have been providing every support to the inquiry team and will continue to do so.

"We are also providing support to both patients and staff throughout the process.

Mr Slorance, a former journalist, was the first head of media relations for the Scottish Parliament after its creation in 1999 and was Alex Salmonds official spokesman between 2007 and 2010.

In 2012, he joined the governments resilience division as head of the response and communications unit responsible for responding to and planning for major emergencies.

Mr Slorance was first diagnosed with mantle cell lymphoma in 2015, but the disease had recently returned. He had been due to undergo a stem cell transplant, but the procedure was postponed due to the coronavirus pandemic.

He wrote a popular blog about his battle with the disease and raised a significant amount of money for cancer charities most recently a 300-mile cycle challenge, which he undertook just months before his death.

See the original post:
FMQs: Senior Glasgow doctor warns claims doctors act in secret or conceal information could damage public confidence as Andrew Slorance widow claims...

Former Tranmere player Gary Stevens’ son dies after battle with leukaemia – The Chester Standard

FORMER Tranmere and England star Gary Stevens' son Jack has died following a courageous battle with leukaemia.

Gary, who also played for Everton and Rangers, had revealed last year that four-year-old Jack, was diagnosed with Juvenile myelomonocytic leukaemia (JMML), a rare form of blood cancer that affects young children.

Jack had been responding well to treatment but he was forced to restart chemotherapy with doctors indicating he desperately needed a stem cell donor.

In September, Gary, 58, spoke to Everton's website about Jack's prognosis.

As you can imagine, this is the worst possible news for all of us, said Gary, who lived in Bromborough for many years until he moved to Australia in 2011.

He was doing so well, and the search is back on for a suitable stem cell donor."

The Goodison Park club had appealed for donors to come forward in an effort to help their former player who played over 200 times for the Toffees.

Everton announced the news of Jack's death on their Twitter page with a picture of Gary and Jack.

The club wrote: "Everyone at Everton is deeply saddened to learn that Gary Stevens four-year-old son, Jack, has passed away following his courageous battle with leukaemia.

"Our thoughts are with Gary and his family at this incredibly sad time."

Tranmere also joined the tributes on Twitter.

They wrote: "The thoughts of everyone at Tranmere Rovers are with Gary Stevens and his family at this sad time."

Gary signed for Rovers inn September 1994 for a fee of 350,000. He featured regularly at right back for the Prenton Park club over the next four seasons, making 127 league appearances and helping them qualify for the Championship playoffs before managing three successive mid table finishes. He retired from playing at the end of the 199798 season.

He also played for England winning a total of 46 appearances, and playing at the World Cup in both 1986 and 1990.

Read more from the original source:
Former Tranmere player Gary Stevens' son dies after battle with leukaemia - The Chester Standard

Braeden Lichti – Investing in Precision Medicine to Yield New Treatments for Neurodegenerative Diseases – PRNewswire

VANCOUVER, BC, Nov. 18, 2021 /PRNewswire/ --Advances in the collective genetic understanding of diseases, and the ability to identify disease biomarkers, is ushering in a new era of personalized medicine. Technologies such as CRISPR/Cas9 are also paving the way for improved, more tailored treatments targeted to a specific genetic marker of a disease. As our understanding of the molecular underpinnings of disease continue to improve, so, too, will the technologies at our disposal to treat them.

We've already seen the benefits of this type of personalized medicine in the cancer realm. Using a person's (or disease's) genes to drive cancer therapy is known as precision medicine. Precision medicine can help doctors identify high-risk cancer patients, choose treatment options, and evaluate treatment effectiveness. Precision medicine can also be used to prevent certain types of cancer, diagnose certain types of cancers early (leading to earlier treatment and better outcomes), and diagnose specific types of cancer more correctly.

As targeted therapies continue to advance, we will continue to see their impacts flow beyond that of the cancer realm. One area in which interest is ramping up is neurodegenerative diseases, which are chronic, progressive diseases affecting the brain and its constituent cells. Neurologic disease can be genetic, or caused by a stroke or brain tumor. Examples of neurodegenerative disease include Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease. These diseases have a genetic component, with specific genes playing a role in the development and progression of disease, especially in rare forms. Neurodegenerative conditions, like cancer, are devastating and costly. Collectively, neurodegenerative conditions cost people in the United States $655 billion in 2020.

Can we apply concepts from targeted therapies developed for cancer to create better outcomes for patients suffering from neurodegenerative diseases? What's more, can precision medicine be used to treat other large unmet needs in the field of neurology, such as neuropsychiatry, pain, epilepsy, sleep disorders, and stroke?

Precision medicine in neuroscience and neurology is where many companies have dedicated their time and efforts. Three companies trading on the NASDAQ in this space that investors should research are Alnylam, Ionis Pharmaceuticals, and Regeneron.

Neuroscience research companies are clamoring to make use of the plethora of cellular and molecular biology data that is emerging about drugs and the patients who use them. There is much more information to be gleaned from diseases and patients than the genetics, which may not reveal information about the ways that genes are formally transcribed and expressed. Emerging technologies, therefore, also look at the RNA profiles of a drug response, patient, or disease state, called transcriptomics; and the set of proteins expressed by a cell, tissue, or organism, called proteomics. While a challenge with gene therapy is reimbursement by insurance providers, research is underway that can make gene therapies more common, and pave the way for more established insurance structures.

RNA targeting is an active area of research for neurodegenerative disease, with companies such as Skyhawk Therapeutics, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, and Takeda involved. By modifying genetic transcription via RNA technologies, these companies hope to develop novel treatments for disorders of the central nervous system. The study of RNA profiles in a given cell, tissue, or organism is known as transcriptomics, and this area will likely heat up as these researchers work to develop pioneering RNA technologies to target neurodegenerative disease.

Proteomics, or the study of the proteins expressed by a cell, tissue, or organism, will also play a role in precision medicine for neurological disorders. In June 2021, the United States Food and Drug Adminstration approved the first therapy addressing the underlying biology of Alzheimer's disease. The drug, Biogen's Aducanumab, is a monoclonal antibody therapy that works by clearing a substance known as beta-amyloid, a protein that scientists believe causes Alzheimer's, from the brain. The drug, which was found to exhibit a unique proteomic profile upon treatment in mice, was the first approved for Alzheimer's in 20 years, and while it is thought to be effective in a limited number of Alzheimer's disease cases (namely, people in the early stages of Alzheimer's), it represents a step forward in neurodegenerative disease research.

The FDA's approval of Aduhelm, which was under an accelerated timeframe, has created more interest in the area of Alzheimer's and Parkinson's disease treatments. Scientists believe that a protein called tau is more closely associated with dementia than beta-amyloid, so they are also seeking to develop drugs targeting tau protein. In the realm of Parkinson's disease, research is underway to target a compound called alpha-synuclein, which, like amyloid beta and tau protein in Alzheimer's, is associated with cognitive decline in Parkinson's disease. There are a number of approaches in development to target tau. Investors can expect many more biotech companies and venture firms moving into this space to develop innovative and alternative treatments.

This work is not without significant challenges. One obstacle in neurodegenerative research is creating drugs that can bypass the brain's blood-brain-barrier, which keeps the brain safe from toxic substances or pathogens that would otherwise make their way into the brain. Another challenge is the fact that neurodegeneration affects a subset of neurons, which may have different levels of vulnerability to such disease. It is not yet fully clear which factors predispose certain neurons to develop pathology over others.

Yet as drug discovery continues to leverage the latest techniques in genomics, transcriptomics, and proteomics, and combinations of these technologies, this will unlock new potential for companies to create novel, increasingly personalized, therapies. For example, advances in genomics may provide insight into how neurodegeneration occurs in the brain.

Drug discovery in neurodegeneration also overlaps with that of other diseases, due to common disease pathways. For example, phosphatidylinositol 3-Kinase (PI3K) inhibitors are implicated not only in COVID-19 and breast cancer, but also Parkinson's Disease. Stem cell therapies, which could benefit patients suffering from many conditions, can also have significant applications in the neurodegenerative realm. Stem cells could potentially be used to restore lost brain tissue, or to release compounds such as anti-inflammatory factors and growth factors supporting repair of the nervous system. Stem cell therapies, which are already in use for conditions such as cancer, could thereby restore function to neurodegenerative patients. Therefore, advances made in the treatment of other disease states could potentially innovate the field of neurodegeneration as well.

PRLog ID: http://www.prlog.org/12894142

SOURCE Braeden Lichti

Read the original post:
Braeden Lichti - Investing in Precision Medicine to Yield New Treatments for Neurodegenerative Diseases - PRNewswire

Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15% – PRNewswire

PALM BEACH, Fla., Nov. 16, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. Also, the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, to be postponed unless the risks outweighed the benefits and to secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the cancer therapy market. However, the situation is expected to gradually improve. According to a reportfrom Mordor Intelligence the global cancer therapy market was valued at approximately USD 158 billion in 2020, and it is expected to witness a revenue of USD 268 billion in 2026, with a CAGR of 9.15% over the forecast period. Active companies in the markets today include: Hoth Therapeutics, Inc. (NASDAQ:HOTH), Cassava Sciences, Inc. (NASDAQ: SAVA), Biogen Inc. (NASDAQ: BIIB), Camber Energy, Inc.(NYSE: CEI), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT).

The report continued: "The factors that are driving the market growth include increasing patient assistance programs (PAPs), increasing government initiatives for cancer awareness, rising prevalence of cancer worldwide, and strong R&D initiatives from key players, along with the increasing demand for personalized medicine The increasing incidence of cancer cases is expected to drive the need for advanced cancer therapies for the effective treatment of patients. Thus, given the aforementioned factors, the cancer therapy market is expected to witness tremendous growth over the forecast period. Targeted therapy is a rapidly growing field of cancer research, and researchers are studying many new targets Thus, in view of the increasing product approvals and high research activities related to targeted therapies against cancers, the studied segment is expected to grow over the forecast period."

Hoth Therapeutics, Inc. (NASDAQ:HOTH) BREAKING NEWS: Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT Hoth Therapeutics, Inc., a patient-focusedbiopharmaceutical company,today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC State") to support the continued research and development of HT-KIT, a novel therapeutic for the treatment mast cell cancers.

The research will be led by Dr. Glenn Cruse, Assistant Professor, and will focus on characterizing the HT-KIT dose and dosing frequency for treatment of aggressive mastocytosis and mast cell neoplasms using humanized tumor mouse models. In addition, the research will expand therapeutic potential of HT-KIT for the treatment of other cancers where aberrant cKIT signaling contributes to the cancer progression, such as gastrointestinal stromal tumors (GIST) and acute myeloid leukemia (AML).

"We are pleased to announce the continuation of our development of HT-KIT after our earlier announcement of beginning API and drug product manufacturing," said Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics, Inc. "We remain focused on pushing this important cancer therapeutic through to the clinic. The research conducted by Dr. Cruse and NC State will help direct the continued development and clinical planning of this potentially life-saving therapy."

About HT-KIT - HT-KIT is a new molecular entity (NME) under development for treatment of mast cell derived cancers and anaphylaxis. HT-KIT was developed Dr. Glenn Cruse, Assistant Professor at North Carolina State University. The HT-KIT drug is designed to more specifically target the receptor tyrosine kinase KIT in mast cells, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as gastrointestinal stromal tumors and mast cell-derived cancers (mast cell leukemia and mast cell sarcoma). Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis. The same target, KIT, also plays a key role in mast cell-mediated anaphylaxis, a serious allergic reaction that is rapid in onset and may cause death. Anaphylaxis typically occurs after exposure to an external allergen that results in an immediate and severe immune response. CONTINUED Read the Hoth Therapeutics full press release by going to: https://ir.hoththerapeutics.com/news-releases

In other news and developments of note in the markets this week:

Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, recently announced financial results for the third quarter ended September 30, 2021. Net loss for the third quarter ended September 30, 2021, was $9.6 million, or $0.24 per share, compared to a net loss of $1.4 million, or $0.06 per share, for the same period in 2020. Net cash used in operations was $22.2 million during the first nine months of 2021. Net cash use for operations for full-year 2021 is expected to be approximately $25 to $30 million, up from previous guidance of $20 to $25 million due to a significant prepayment made to a contract research organization for our Phase 3 clinical program with simufilam. An additional $22.0 million was used during the third quarter of 2021 for an all-cash purchase of an office complex in Austin, Texas, which will serve as the Company's future corporate headquarters. Cash and cash equivalents were $241.5 million as of September 30, 2021, with no debt.

Camber Energy, Inc.(NYSE American: CEI) recently announced its majority-owned subsidiary, Viking Energy Group, Inc., entered into an Exclusive Intellectual Property License Agreement with ESG Clean Energy, LLC ("ESG") regarding ESG's patent rights and know-how related to stationary electric power generation, including methods to utilize heat and capture carbon dioxide. The license is exclusive for all of Canada (unlimited number of systems), and non-exclusive for up to twenty-five locations in the United States.

Biogen Inc. (NASDAQ: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) recently announced that data from approximately 7,000 plasma samples from more than 1,800 patients in the ADUHELM (aducanumab-avwa) Phase 3 clinical trials showed a statistically significant correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer's disease. Reductions in plasma p-tau181 were also correlated with a lowering of amyloid beta plaque. The pre-specified analysis of plasma samples was conducted by an independent lab, drawing from the two pivotal ADUHELM Phase 3 EMERGE and ENGAGE trials. The findings were presented today at the Clinical Trials on Alzheimer's Disease conference (CTAD), held November 9-12 virtually and in Boston, Massachusetts.

The analysis highlighted that ADUHELM significantly reduced tau pathology, a defining feature of Alzheimer's disease, as measured by plasma p-tau181, when compared to placebo. The effect was greater with higher doses and longer duration of ADUHELM treatment. Greater reduction in plasma p-tau181 also had a statistically significant correlation with less decline in cognition and function in ADUHELM-treated patients. Furthermore, the analysis demonstrated a statistically significant correlation between change in plasma p-tau181 and lowering of amyloid beta plaque, showing the effect of ADUHELM on the two core pathological features of Alzheimer's disease.

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, recently announced results from a new analysis examining obeticholic acid's (OCA) potential to improve transplant-free survival in patients with PBC. The data will be featured in a late-breaking podium presentation at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held virtually from Friday, November 12 to Monday, November 15, 2021. The analysis was also selected as a "Best of The Liver Meeting" abstract in the Cholestatic and Autoimmune Liver Diseases category.

"This collaborative study used an innovative approach to contribute new understandings about how treatment of patients with PBC with OCA may impact clinical outcomes: we compared patients with PBC who were treated with OCA in the open-label long-term safety extension of the Phase 3 POISE trial, with external controls from two large representative academic-led patient registries. When compared to real-world patient outcome data, the results provide insights into OCA's potential to improve transplant-free survival in patients with PBC treated in a trial setting," said Professor Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto. "Data describing the effect of OCA on mortality and need for liver transplant in patients with PBC is eagerly awaited, but such data is inevitably challenging to generate. Notably, when doing this comparison, we found consistent results across the two databases. We hope this analysis can soon be extended to include more patients treated with OCA, and approaches such as this can help the field overcome obstacles to generating meaningful clinical outcome data."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by: Hoth Therapeutics, Inc. by a non-affiliated third party.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:Media Contact email: [emailprotected] - +1(561)325-8757

SOURCE FinancialNewsMedia.com

See original here:
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15% - PRNewswire

Indiana’s top doctors frustrated about the state’s COVID-19 vaccination rate – 953mnc.com

The states top doctors are frustrated because nearly half of the population who can get the vaccine have not done it. Now hospitals are having to put off some surgeries and procedures to take care of people who need hospitalization because of COVID-19.

Forty-eight percent of our eligible population remains unvaccinated, said Chief Medical Officer Dr. Lindsay Weaver, in an update from the state Dept. of Health, Friday. That statistic allows the virus to continue to thrive and puts those who cannot yet be vaccinated at greatest risk.

But, Weaver said there has been some improvement in the last week.

We have noticed an increase in Hoosiers scheduling their vaccine, she said. Weaver noted a ten percent increase in appointments.

Both Weaver and state Health Commissioner Dr. Kris Box said the state is having some trouble keeping up with the demand for testing. Box said that only ten percent of schools across the state reported being able to offer tests for students. The Dept. of Health is working to remedy that capacity issue.

Almost all of the new coronavirus activity is attributed to the Delta surge.

Weaver also said that guidance points to you getting a third dose of the vaccine, either Pfizer or Moderna, if you meet the following criteria: people undergoing treatment for cancer; recipients of solid organ or stem cell transplants; people with advanced or untreated HIV; and people who are taking certain medications that suppress the immune system.

Weaver also said you can expect information in the fall about a booster shot for anyone who has gotten the vaccine.

Both said the majority of people who have been hospitalized or who have died from COVID were not vaccinated.

Box said you are still going to be seeing large numbers of people testing positive for coronavirus for a while. She called this the darkest part of the pandemic.

Unfortunately we have many more weeks of this high level of activity before we can expect this Delta surge to start declining.

Excerpt from:
Indiana's top doctors frustrated about the state's COVID-19 vaccination rate - 953mnc.com

OpRegen: tackling the leading cause of blindness with cell replacement – Clinical Trials Arena

Clinical Trials Arena speaks to Lineage Cell Therapeutics CEO Brian Culley about the firms lead candidate OpRegen for dry AMD and the unexpected cases of retinal restoration in an ongoing Phase I/IIa trial.

Age-related macular degeneration (AMD) is one of the worlds leading causes of blindness in people over the age of 50. There are two types of the disease wet AMD and dry AMD.

The less common wet AMD is well understood as being caused by leaky blood vessels and has numerous effective treatments available. Dry AMD causes layers of the macula (including the photoreceptors and the retinal pigment epithelium) to get progressively thinner and function less and less well. This is called atrophy.

Advanced cases of dry AMD are known as geographic atrophy (GA) because large sections of the retina stop functioning.

There are around two million people in the US suffering with this severe form of the condition, and there are currently no treatments available, representing a huge unmet need. Historically, dry AMD has been viewed as an inevitably progressive disease.

California-headquartered Lineage Cell Therapeutics is taking a very different approach to the disease compared to traditional pharmaceutical approaches, which often involve targeting inflammation with small molecules and antibodies and treating patients either orally or locally in the eye.

With its lead candidate OpRegen, which is in an ongoing Phase I/IIa open-label clinical study, Lineage is manufacturing brand new retina cells and taking a transplant approach to the condition.

Its been very exciting what we have seen in the clinic so far, the companys CEO Brian Culley tells Clinical Trials Arena.

The one-time therapy consists of allogeneic retinal pigment epithelium (RPE) cells and is administered subretinally in patients with dry AMD and GA. The patient is locally anaesthetised and the procedure only takes about 30 minutes.

The firm uses pluripotent stem cells as a starting material to manufacture the therapy. Just as flour can become bread or a cookie, [pluripotent] stem cells have within them the capability or the capacity to become any of the 200 cell types in your body, says Culley.

We instruct the cells to become a specific and exclusive type of cell and then we transplant those into the body. In the case of dry AMD we manufacture enormous numbers of retina cells and only retina cells, and then we transplant those cells to treat disease of the eye.

The manufacture of cells requires exquisite control over your process as you are manufacturing a dynamic living entity at scale, Culley says. If you cannot manufacture at large scale, you will never have an economically affordable solution.

The allogeneic rather than autologous nature of Lineages manufactured retinal cells provides advantages in scale, he argues.

There are approaches that people take even in dry AMD where they take cells from a persons eye, and they manipulate them and then they replace them, but here youre talking about personalised medicine, which sounds great until you consider the cost.

Weve invested significantly in our manufacturing skills and created a huge number of patents from our manufacturing techniques. We are already at the point where, in a three-litre bioreactor, we can manufacture the equivalent of 2500 clinical courses so many thousands of treatments can come from basically a milk jug and scaling up is straightforward because we grow the cells on little microcarriers. We grow the cells in three-dimensional space and that allows us to increase the volume because the cell doesnt really know the difference between growing in a tiny thimble or growing in a swimming pool.

Cell therapy brings with it the complexity of dealing with a whole cell rather than just a single molecule, but that complexity is also the key to this approach.

By the time retina cells are dying off, there are so many things going wrong in the eye that we dont think that a single molecule is going to have enough horsepower to be able to drive a clinical outcome, Culley says. So we think you have to replace the entire cell.

The ongoing Phase I/IIa clinical trial evaluating OpRegen enrolled 24 people. Twelve of the participants treated with the therapy had very advanced AMD and were legally blind.

Culley says this cohort was used to assess the treatments safety and not much was seen in terms of efficacy but some encouraging anatomical changes were observed.

In the eye, the vision cycles metabolic activity leads to a waste material called drusen, which is cleared by healthy retina cells. In some of these patients, a reduction in drusen was observed.

The next group of 12 patients disease was far less advanced and they had far better baseline vision than the first; some even still had their drivers licenses. At their earlier stage of disease, they had more retinal tissue with potential to be rescuable. When the trial moved into the group of patients with better starting vision, Culley and his team started to see very exciting effects in terms of visual acuity and anatomical changes.

We were really happy to see that in that group of individuals, weve had better results, Culley says. We have seen an increase in vision, so people are seeing more letters on an eye chart, compared to their untreated eye. The majority of untreated eyes have gotten worse, which is what you would expect over time. In the treated eye it is reversed; weve actually seen people gain vision.

No patients in the trial, which started treating patients with OpRegen five years ago, have rejected the cells, meaning all have stably integrated them. Most exciting of all are three cases of retinal restoration, which Culley says is really unprecedented stuff due to the progressive nature of the disease.

This is a new phenomenon, says Culley. Human beings cannot regenerate retinal tissue; when you lose retina cells, theyre gone forever. And thats what this disease is all about losing retina cells.

Over a year ago, while looking at images of a patients eyes after OpRegen treatment, doctors noticed retina cells growing back around the spot of GA.

We were absolutely blown away, Culley says. We actually sat on this initial finding for quite some time, because even though it was incredible, and exciting and maybe even predictable in some ways youre transplanting cells and if theyre taken up, survive and are functional why wouldnt this happen but nobody thought it was possible.

The question the firm focused on while analysing the data and sending it out to third-party independent retinal imaging experts was simple why did this patient experience retinal tissue regeneration while no one else did?

We think the answer was that patient got a very complete delivery of our cells all across that atrophic area, explains Culley.

Lineage repeated the procedure and got similarly extensive coverage across another two patients, and they also exhibited retinal restoration. So we now have three cases that have exhibited retinal restoration. Now its not a one-time thing we have some understanding, we could reproduce it, its quite clear.

One of the trial participants atrophy originally got smaller but now has grown back to the size it was three years ago meaning that essentially her AMD had been halted.

In the three years since I had the operation, the eye that was operated on has not deteriorated which I reckon is almost miraculous, said the patient, Sonia Cohen. Its really amazing. I cant imagine what my life would have been like if I had continued to deteriorate.

Culley says that with OpRegens clinical research thus far, his team has learned that being more aggressive with where they place the cells leads to better outcomes.

Now we know that so we can repeat that. I think over time, it will get better and better, and Id be really delighted if we get up to the point where it becomes like LASIK surgery, which is close to 100% success rate.

Later this year, Lineage is planning to discuss the design of its next trial with the US Food and Drug Administration. For now, the three cases of retinal restoration or reversal of AMD have provided a vital proof of concept.

We want to go as quickly as possible into the next study, and having the backing of this reversal is very exciting because, from a statistical perspective, we probably dont need 2,000 patients were talking about hundreds of patients.

On the future of cell therapy, Culley says it is a field that is quickly maturing. It used to be like the wild west but now companies like ours are doing these rigorous clinical trials to find out ways to control it and dry AMD is a really cool place to start, he says. But, there are 199 other cell types that we could investigate so there is a long-term medical story here that is really about ushering in a new branch of medicine manufacturing cells, transplanting them that Im really excited to be part of.

Dry AMD is not the firms only focus; it has also embarked on clinical trials for VAC2, an allogeneic dendritic cell therapy currently enrolling a Phase I trial for the treatment of non-small cell lung cancer and has treated 25 people with spinal cord injuries with its candidate OPC1 in a Phase I/II trial, which Culley says has been very emotional.

I know if I live long enough my retina cells are going to die off; if I smoke four packs of cigarettes [a day] I will get lung cancer, but nobody expects to get a spinal cord injury. All of these young people who fall off mountain bikes or get in car crashes and their lives are turned upside down. Their ability to just get some hand control to be able to move their wheelchair thats mobility and independence so if we can help regain mobility, thats freedom so I think the spinal cord program is really powerful.

Electronic Data Capture Solutions for Clinical Trials

Bespoke, Cost-Effective Preclinical Cancer Model Searches for Preclinical Studies

Drug Processing Technology and Laboratory Equipment

Electronic Data Capture Solutions for Clinical Trials

28 Aug 2020

Bespoke, Cost-Effective Preclinical Cancer Model Searches for Preclinical Studies

28 Aug 2020

Drug Processing Technology and Laboratory Equipment

28 Aug 2020

Link:
OpRegen: tackling the leading cause of blindness with cell replacement - Clinical Trials Arena

I blamed stress for my three-month period but it turned out to be much more sinister… – The Sun

A WOMAN blamed stress for her three-month long period until doctors found out the true cause was devastating.

Bansri Dhokia, 30, from Ealing, West London, is now urging others to see their GP as soon as they are unwell.

8

She thought at worst, her odd periods, fatigue and breathlessness would be down to anaemia or low thyroid function that could be treated with medication.

But the truth was far worse, and Bansri was diagnosed with a blood cancer.

Bansri was taken into hospital that night where she stayed for 12 weeks having intense treatment to save her life.

Speaking of her symptoms, which started in May 2020, Bansri said: I blamed it on being overworked.

With blood cancer, the symptoms are often quite vague and hard to diagnose.

I really noticed the fatigue first. I could sleep for 12 hours a night and still feel exhausted.

Then I started to get breathless all the time. There were activities like climbing stairs or walking down the road that I used to find easy but was suddenly finding more difficult.

Bansris heavy period, which had been ongoing for three months, was particularly unusual for her.

She made repeated trips to the doctor to find out what was wrong but kept being pushed back.

I just knew something wasn't right and repeatedly asked for blood tests, Banrsri said.

The first four blood tests between May and July came back clear and by the time she had a fifth on 21 July, she was starting to get fed up.

Busy with work, Bansri almost missed the appointment but luckily, her husband Amrit Sagoo encouraged her to go.

She said: I went for the blood test in the afternoon and that evening, I was brushing my teeth when I got a call to say the ambulance was coming to collect me.

They explained I needed to go to hospital right away. I thought it was just for a night and packed an overnight bag.

"I didnt know what was wrong and that I would end up staying in hospital for 12 weeks.

Tests at the Royal London hospital revealed Bansri had acute lymphoblastic leukaemia (ALL), a rare cancer affecting just 790 people in the UK each year, mostly children and young people.

8

8

8

A problem in the bone marrow leads to insufficient important blood cells, causing symptoms of unusual bleeding, tiredness and muscle aches.

Almost seven in 10 will survive ALL for five years or longer after diagnosis, and four in ten in those aged 25 to 64.

Bansri said: I didn't know much about leukaemia. I was really scared for my life. I had no idea what the prognosis was. I just cried and I kept questioning why this was happening to me."

With lockdown restrictions still in place, Bansri had to tell her friends and family about her diagnosis over Zoom.

She said: It was the hardest thing I have ever had to do. I asked my sister to gather my family in the living room. We are very close and I could not look at her because I just couldn't deal with seeing the sadness in her face."

Bansri started chemotherapy straight away, because ALL is very aggressive and develops quickly.

She said: "It was so upsetting seeing pieces of my hair fall out on my pillow. I was growing it as we were planning to have Hindu and Sikh religious wedding ceremonies in 2020, after our civil wedding the year before.

"One day I just asked the nurse to shave my head, and in that moment, I felt really empowered."

But one of the hardest parts of the treatment - which she now needs therapy to recover from - is that she couldnt have visitors for the first eight weeks due to Covid.

8

8

Bansri then needed a stem cell transplant to improve the chances that she would go into remission.

During the procedure, the patient has stem cells of a donor, sometimes a complete stranger, injected into their blood. The cells find their way to the bone marrow, helping it to start making normal cells again.

Most people who are white Europeans find a match from a related or unrelated donor on a large registry, but 400 UK patients don't find a suitable donor each year.

Bansri said: I knew immediately that being from an Indian background, there was a very low chance that I would find a match.

According to charities, donors are more likely to be white, and people from minority ethnic backgrounds are more likely to have rarer tissue types, making it harder to find patients from these backgrounds a matching donor.

That was quite scary because I knew how important it was to have a donor to save my life, Bansri said.

Luckily one of Bansris two siblings was a match, and the transplant took place in February 2021.

Bansri said: My recovery is going well so far but a stem cell transplant comes with many side effects, which are lifelong.

I have a long road to go but I take it day by day. Each month I get through is a success."

Bansri is vulnerable to infections because the transplant made her immune system weaker, and so she and her husband are still having to shield.

Bansri is urging people to join the stem cell donor register, particularly those in Asian communities.

REGISTERING to be a blood stem cell donor is easy.

Even if you can't donate to your relative, you might be ableto become a donor for someone else. You can do this by contacting one of the UK registers.

There are different donor registersin the UK.These work with each otherand with international registersto match donors with people who need stem cells.

You can sign up with:

8

8

She said: People often have a misconception that, when you join the donor registry, you're giving something up, for example, in a kidney transplant, you do give up your kidney, and it's a longer recovery time.

My sibling was in hospital for a few hours on the day and didn't have any side effects afterwards.

In my community, cancer is a bit of a taboo subject and people dont speak about it so I think there is a lack of awareness of the importance of signing up to be on the register.

Bansri is also taking part in the Leukaemia Cares Spot Leukaemia campaign, which urges the general public to understand and recognise the signs.

She said: I want to see more Asian people talking about it because its not the fault of the person - its just bad luck.

If youre experiencing any of the symptoms, contact your GP and ask for a blood test. Early diagnosis saves lives.

The NHS says most of the symptoms of ALL are caused by a lack of healthy blood cells. They include:

In some cases, the affected cells can spread from your bloodstream into your central nervous system. This can cause neurological symptoms (related to the brain and nervous system), including:

More here:
I blamed stress for my three-month period but it turned out to be much more sinister... - The Sun